银屑病关节炎III期随机对照试验中b/tsDMARDs受试者人口学特征的演变:一项系统综述
该系统综述纳入截至2022年6月1日发表的34项安慰剂对照III期RCT,分析外周型银屑病关节炎b/tsDMARDs试验受试者人口学特征随时间的变化。女性比例从2000-2004年启动研究的29.0-43.7%升至2015-2019年的46.0-58.8%,参与国家数从1-8个增至2-46个,但白人比例仅从90.0-98.0% marginal 变为80.9-97.3%,非白人受试者仍代表不足。
要点
- 女性受试者比例随时间上升,从2000-2004年启动研究的29.0-43.7%增至2015-2019年的46.0-58.8%。
- 参与国家数从2000-2004年的1-8个增至2015-2019年的2-46个,但白人比例仅从90.0-98.0%变为80.9-97.3%。
- 非白人受试者仍代表不足,作者认为改善患者代表性多样性对推进银屑病诊疗至关重要。
核心结论
- 尽管银屑病关节炎RCT受试者招募国家范围扩大,非白人受试者仍代表不足。
- 作者认为改善患者代表性多样性对深入理解银屑病关节炎表型、蛋白质基因组学、社会经济决定因素和治疗效果至关重要,以推进所有银屑病患者的诊疗。
研究设计与样本
- 系统综述,检索EMBASE、MEDLINE和Cochrane临床对照试验数据库(CENTRAL),纳入截至2022年6月1日发表的以外周型银屑病关节炎为对象的b/tsDMARDs安慰剂对照III期RCT。
- 共纳入来自33篇报告的34项符合标准的RCT,提取纳入标准、启动日期、研究国家、年龄、性别、种族、病程、肿胀关节数、压痛关节数、HAQ-DI、PASI和影像学损伤评分,采用描述性统计分析随时间的变化趋势。
主要发现
- 女性受试者比例随时间增加:2000-2004年启动的研究中女性占29.0-43.7%,2015-2019年升至46.0-58.8%。
- 参与国家数从2000-2004年的1-8个增至2015-2019年的2-46个。
- 白人受试者比例从2000-2004年的90.0-98.0% marginal 变化至2015-2019年的80.9-97.3%。
- 肿胀关节数和压痛关节数分别从2000-2004年的13.9-24.6降至2015-2019年的7.0-13.9和12.9-24.9。
- 基线CRP和HAQ-DI保持稳定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize the evolving demographics of participants recruited to phase III randomised controlled trials (RCTs) of biologic/targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in peripheral psoriatic arthritis (PsA). METHODS: We conducted a systematic review of EMBASE, MEDLINE, and the Cochrane Database of Clinical Trials (CENTRAL) to identify all placebo-controlled phase III RCTs of b/tsDMARDs in peripheral PsA published up to 1 June 2022. Data extracted included inclusion criteria, date of initiation, countries in which studies were conducted, age, sex, race, disease duration, swollen joint count, tender joint count, Health Assessment Questionnaire - Disability Index, Psoriasis Area and Severity Index, and radiographic damage scores. Trends over time were evaluated using descriptive statistics. RESULTS: 34 eligible RCTs from 33 reports were included. The proportion of female participants increased over time with females representing 29.0-43.7% of participants in studies initiated in 2000-2004 which increased to 46.0-58.8% in 2015-2019. While the number of countries included in RCTs increased significantly from 1-8 countries (2000-2004) to 2-46 (2015-2019), the proportion of white participants changed marginally from 90.0-98.0% (2000-2004) to 80.9-97.3% (2015-2019). The SJC and TJC decreased from 13.9 to 24.6 respectively (2000-2004), to 7.0-13.9 and 12.9-24.9 (2015-2019). Baseline CRP and HAQ-DI remained stable. CONCLUSION: Despite the expansion of countries from which PsA RCT participants were recruited from, non-white participants continue to be under-represented. Improving diversity in patient representation is imperative to further our understanding of PsA phenotypes, proteogenomics, socioeconomic determinants, and treatment effects, to advance the care of all patients with psoriatic disease.
引用
- Zhu W, Ayoub S, Morand E, et al. The evolving demographics of participants in psoriatic arthritis phase III randomised controlled trials of b/tsDMARDs: A systematic review. Semin Arthritis Rheum. 2023. PMID: 36803867. doi:10.1016/j.semarthrit.2023.152175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。